BR112021011753A2 - Composição - Google Patents
Composição Download PDFInfo
- Publication number
- BR112021011753A2 BR112021011753A2 BR112021011753-9A BR112021011753A BR112021011753A2 BR 112021011753 A2 BR112021011753 A2 BR 112021011753A2 BR 112021011753 A BR112021011753 A BR 112021011753A BR 112021011753 A2 BR112021011753 A2 BR 112021011753A2
- Authority
- BR
- Brazil
- Prior art keywords
- aqueous solution
- acid
- composition
- solution composition
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1821149.0A GB201821149D0 (en) | 2018-12-21 | 2018-12-21 | Novel composition |
| GB1821149.0 | 2018-12-21 | ||
| GB1911581.5 | 2019-08-13 | ||
| GBGB1911581.5A GB201911581D0 (en) | 2019-08-13 | 2019-08-13 | Novel composition |
| PCT/GB2019/053655 WO2020128507A1 (en) | 2018-12-21 | 2019-12-20 | Novel composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021011753A2 true BR112021011753A2 (pt) | 2021-08-31 |
Family
ID=69104798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021011753-9A BR112021011753A2 (pt) | 2018-12-21 | 2019-12-20 | Composição |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12239685B2 (https=) |
| EP (2) | EP3897573A1 (https=) |
| JP (2) | JP7421556B2 (https=) |
| KR (1) | KR20210114000A (https=) |
| CN (2) | CN113301885A (https=) |
| AU (1) | AU2019411551A1 (https=) |
| BR (1) | BR112021011753A2 (https=) |
| CA (1) | CA3124529A1 (https=) |
| WO (2) | WO2020128507A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12239685B2 (en) | 2018-12-21 | 2025-03-04 | Arecor Limited | Composition |
| WO2020229369A1 (en) * | 2019-05-10 | 2020-11-19 | Xellia Pharmaceuticals Aps | Daptomycin aqueous formulations |
| EP4117625A1 (en) | 2020-03-12 | 2023-01-18 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
| CN116726145A (zh) * | 2022-03-04 | 2023-09-12 | 海南普利制药股份有限公司 | 一种稳定的酯肽类药物组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US6716962B2 (en) | 2000-07-17 | 2004-04-06 | Micrologix Biotech Inc. | Extractive purification of lipopeptide antibiotics |
| WO2002059145A1 (en) | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| IL156394A0 (en) | 2000-12-18 | 2004-01-04 | Cubist Pharm Inc | Methods for preparing purified lipopeptides |
| US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| CN100421726C (zh) | 2006-03-06 | 2008-10-01 | 南京凯瑞尔纳米生物技术有限公司 | 包含有肽类药物的纳米复合物滴眼液及其制备方法 |
| WO2011035108A1 (en) | 2009-09-17 | 2011-03-24 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| WO2011062676A1 (en) | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| US20170348382A1 (en) * | 2014-12-16 | 2017-12-07 | Dr. Reddy's Laboratories Limited | Lyophilized injectable compositions of daptomycin |
| WO2018073269A1 (en) * | 2016-10-21 | 2018-04-26 | Xellia Pharmaceuticals Aps | Liquid formulations of daptomycin |
| RU2770366C2 (ru) * | 2017-08-31 | 2022-04-15 | Кселлия Фармасьютикалз Апс | Препараты даптомицина |
| US12239685B2 (en) | 2018-12-21 | 2025-03-04 | Arecor Limited | Composition |
| WO2020229369A1 (en) | 2019-05-10 | 2020-11-19 | Xellia Pharmaceuticals Aps | Daptomycin aqueous formulations |
-
2019
- 2019-12-20 US US17/416,677 patent/US12239685B2/en active Active
- 2019-12-20 AU AU2019411551A patent/AU2019411551A1/en not_active Abandoned
- 2019-12-20 WO PCT/GB2019/053655 patent/WO2020128507A1/en not_active Ceased
- 2019-12-20 CN CN201980085068.5A patent/CN113301885A/zh active Pending
- 2019-12-20 CN CN201980085263.8A patent/CN113271922A/zh active Pending
- 2019-12-20 CA CA3124529A patent/CA3124529A1/en active Pending
- 2019-12-20 WO PCT/GB2019/053654 patent/WO2020128506A1/en not_active Ceased
- 2019-12-20 EP EP19831844.6A patent/EP3897573A1/en active Pending
- 2019-12-20 BR BR112021011753-9A patent/BR112021011753A2/pt not_active IP Right Cessation
- 2019-12-20 JP JP2021535273A patent/JP7421556B2/ja active Active
- 2019-12-20 EP EP19831843.8A patent/EP3897572A1/en not_active Withdrawn
- 2019-12-20 JP JP2021535272A patent/JP2022514597A/ja active Pending
- 2019-12-20 US US17/416,661 patent/US20220072090A1/en not_active Abandoned
- 2019-12-20 KR KR1020217023234A patent/KR20210114000A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN113271922A (zh) | 2021-08-17 |
| JP7421556B2 (ja) | 2024-01-24 |
| EP3897572A1 (en) | 2021-10-27 |
| CA3124529A1 (en) | 2020-06-25 |
| AU2019411551A1 (en) | 2021-06-24 |
| JP2022514597A (ja) | 2022-02-14 |
| JP2022514858A (ja) | 2022-02-16 |
| US12239685B2 (en) | 2025-03-04 |
| CN113301885A (zh) | 2021-08-24 |
| US20220072091A1 (en) | 2022-03-10 |
| WO2020128506A1 (en) | 2020-06-25 |
| WO2020128507A1 (en) | 2020-06-25 |
| EP3897573A1 (en) | 2021-10-27 |
| KR20210114000A (ko) | 2021-09-17 |
| US20220072090A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021011753A2 (pt) | Composição | |
| ES2533601T3 (es) | Nueva composición que comprende glucagón | |
| US9107821B2 (en) | Stable bortezomib formulations | |
| US20110230441A1 (en) | Stable bortezomib formulations | |
| PT2349314E (pt) | Formulações de vwf recombinante liofilizado | |
| JP2023029500A (ja) | 抗ヒトｔｓｌｐ受容体抗体含有医薬組成物 | |
| JP2023058632A (ja) | 液体医薬組成物 | |
| CA2784240C (en) | Stable bortezomib formulations | |
| US11154498B2 (en) | Stabilized liquid formulation of levothyroxine | |
| JP2018507848A (ja) | バンコマイシンの水溶液製剤 | |
| CN100544769C (zh) | 包含喜树碱衍生物的液体制剂以及冻干该制剂制得的药物组合物 | |
| WO2017175098A1 (en) | Stable liquid pharmaceutical formulations of bendamustine | |
| WO2018184540A1 (zh) | 包含组氨酸缓冲体系的英夫利西单抗组合物 | |
| US20130149293A1 (en) | Stable compositions of factor ix | |
| US20220080023A1 (en) | Novel composition | |
| JP7423028B2 (ja) | ボルテゾミブを含有する凍結乾燥医薬組成物 | |
| US20220125718A1 (en) | STABILIZED Fc FUSION PROTEIN SOLUTIONS | |
| US20100316592A1 (en) | AQUEOUS PREPARATION COMPRISING eMIP AS ACTIVE INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2860 DE 28-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |